{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T12:08:17Z","timestamp":1792325297770,"version":"4.4.0"},"reference-count":16,"publisher":"Georg Thieme Verlag KG","issue":"07","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Was ist neu?<\/jats:title><jats:p>\n          Kardiovaskul\u00e4res Risikoprofil von Patienten mit entz\u00fcndlichen Gelenkerkrankungen\u2002Patienten mit entz\u00fcndlichen Gelenkerkrankungen leiden h\u00e4ufiger an kardiovaskul\u00e4ren Erkrankungen als die Normalbev\u00f6lkerung. Trotz der Feststellung dieses erh\u00f6hten Risikos vor mehr als einem Jahrzehnt konnte die kardiovaskul\u00e4re Morbidit\u00e4t und Mortalit\u00e4t in dieser Patientengruppe noch nicht gesenkt werden. Auch im Jahr 2021 bleibt das kardiovaskul\u00e4re Risikomanagement von Patienten mit entz\u00fcndlichen Gelenkerkrankungen ein relevanter Aspekt f\u00fcr Haus\u00e4rzte, klinisch t\u00e4tige Rheumatologen und Forschende.<\/jats:p><jats:p>\n          Kardiovaskul\u00e4re Risikobewertung\u2002G\u00e4ngige Berechnungen des kardiovaskul\u00e4ren Risikos f\u00fcr die Normalbev\u00f6lkerung sch\u00e4tzen das Risiko f\u00fcr Patienten mit entz\u00fcndlichen Gelenkerkrankungen oft falsch niedrig ein. Obwohl die Entz\u00fcndung immer wieder als unabh\u00e4ngiger Risikofaktor best\u00e4tigt wird, fehlt es derzeit noch an einem validierten Entz\u00fcndungsparameter, der in Risikoberechnungen integriert werden kann. Zudem muss der Einfluss weiterer krankheitsspezifischen Faktoren \u2013 etwa die Krankheitsaktivit\u00e4t oder die Therapie \u2013 auf das kardiovaskul\u00e4re Risiko untersucht werden. Aktuell existiert noch keine eigenst\u00e4ndige kardiovaskul\u00e4re Risikobewertung f\u00fcr Patienten mit entz\u00fcndlichen Gelenkerkrankungen.<\/jats:p><jats:p>\n          Medikament\u00f6se Beeinflussung des kardiovaskul\u00e4ren Risikos\u2002Krankheitsmodifizierende antirheumatische Medikamente reduzieren das kardiovaskul\u00e4re Risiko. Dieser Effekt konnte in aktuellen Studien besonders f\u00fcr Biologika best\u00e4tigt werden. Tumornekrosefaktor-\u03b1-Inhibitoren senken beispielsweise die Rate der kardiovaskul\u00e4ren Ereignisse um 15\u200a%. Auch Methotrexat, das wahrscheinlich am h\u00e4ufigsten eingesetzte Medikament, kann einen positiven Einfluss auf das kardiovaskul\u00e4re Risiko haben. Daten zu den relativ neuen Januskinase-Inhibitoren werden in den kommenden Jahren erwartet.<\/jats:p>","DOI":"10.1055\/a-1208-2523","type":"journal-article","created":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T22:45:00Z","timestamp":1617057900000},"page":"474-477","source":"Crossref","is-referenced-by-count":4,"title":["Rheuma, Entz\u00fcndung und kardiovaskul\u00e4res Risiko"],"prefix":"10.1055","volume":"146","author":[{"given":"Phuong","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Bereich Rheumatologie, Klinik und Poliklinik f\u00fcr Endokrinologie, Nephrologie und Rheumatologie, Universit\u00e4tsklinikum Leipzig"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Baerwald","sequence":"additional","affiliation":[{"name":"Bereich Rheumatologie, Klinik und Poliklinik f\u00fcr Endokrinologie, Nephrologie und Rheumatologie, Universit\u00e4tsklinikum Leipzig"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2021,3,29]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update","volume":"76","author":"R Agca","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41584-020-0428-y","article-title":"Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis","volume":"16","author":"A G Semb","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease","volume":"377","author":"P M Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1136\/heartjnl-2019-316193","article-title":"Cardiovascular risk factors and outcomes in early rheumatoid arthritis: a population-based study","volume":"106","author":"E Nikiphorou","year":"2020","journal-title":"Heart"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3899\/jrheum.180726","article-title":"Cardiovascular Event Risk in Rheumatoid Arthritis Compared with Type 2 Diabetes: A\u00a015-year Longitudinal Study","volume":"47","author":"R Agca","year":"2020","journal-title":"J Rheumatol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1093\/rheumatology\/kez409","article-title":"Prognostic value of comorbidity indices and lung diseases in early rheumatoid arthritis: a UK population-based study","volume":"59","author":"E Nikiphorou","year":"2020","journal-title":"Rheumatology"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/03009742.2019.1672783","article-title":"Cardiovascular risk factors are highly overrepresented in Swedish patients with psoriatic arthritis compared with the general population","volume":"49","author":"A J Landgren","year":"2020","journal-title":"Scand J Rheumatol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13075-018-1669-x","article-title":"Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study","volume":"20","author":"J L Lee","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3899\/jrheum.171008","article-title":"Performance of the Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis Is Not Superior to the ACC\/AHA Risk Calculator","volume":"46","author":"B Wahlin","year":"2019","journal-title":"J Rheumatol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/art.41122","article-title":"Impact of Cumulative Inflammation, Cardiac Risk Factors, and Medication Exposure on Coronary Atherosclerosis Progression in Rheumatoid Arthritis","volume":"72","author":"G A Karpouzas","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.601344","article-title":"Largely Accelerated Arterial Aging in Rheumatoid Arthritis Is Associated With Inflammatory Activity and Smoking in the Early Stage of the Disease","volume":"11","author":"N Mong","year":"2020","journal-title":"Front Pharmacol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/acr.23567","article-title":"Incidence and Prevalence of Major Adverse Cardiovascular Events in Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis","volume":"70","author":"K Lauper","year":"2018","journal-title":"Arthritis Care Res"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1136\/annrheumdis-2020-217653","article-title":"Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-na\u00efve, early rheumatoid arthritis","volume":"79","author":"S Plein","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/art.41293","article-title":"Biologics May Prevent Cardiovascular Events in Rheumatoid Arthritis by Inhibiting Coronary Plaque Formation and Stabilizing High-Risk Lesions","volume":"72","author":"G A Karpouzas","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/acr.23875","article-title":"Comparative Risk of Cardiovascular Events With Biologic and Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis","volume":"72","author":"S Singh","year":"2020","journal-title":"Arthritis Care Res"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/art.41095","article-title":"Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial","volume":"72","author":"J T Giles","year":"2020","journal-title":"Arthritis Rheumatol"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1208-2523.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T22:46:58Z","timestamp":1617058018000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1208-2523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,29]]},"references-count":16,"journal-issue":{"issue":"07","published-online":{"date-parts":[[2021,3,29]]},"published-print":{"date-parts":[[2021,4]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1208-2523","relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,29]]}}}